STING1 and melanoma: Preclinical studies have shown that the combined use of STING agonists and ICB enhances anti-tumor efficacy (Table 4).734,735 For instance, in advanced mouse models bearing MC38 and B16F10 tumors, the administration of a combination of MK-1454 and the anti-PD-1 antibody mDX400 resulted in a noteworthy reduction in tumor size.730 However, in patients with unresectable or advanced melanoma, the simultaneous use of Epacadostat at a dosage of 100 mg with pembrolizumab did not demonstrate improved progression-free survival or overall survival when compared to pembrolizumab paired with a placebo.